Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects

Uebelhack, Ralf; Bongartz, Udo; Seibt, Stephanie; Bothe, Gordana; Chong, Pee Win; Costa, Patrícia de Moraes; Wszelaki, Natalia

doi:10.1155/2019/3412952

Cited by 10 publications

(14 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, phytochemical analysis has shown that okra was safe up to the dose of 2 g/kg in rats treating with aqueous and methanolic seed extract of okra for 1 week (Doreddula et al, 2014). Moreover, obese patients who take two capsules of okra pods (330 mg of A.esculentus) three times in day for 12 weeks have shown no adverse effect of okra in the performed clinical trial (Uebelhack et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Anti‐hyperglycemic effect of Abelmoschus culentesus (Okra) on patients with diabetes type 2: a randomized clinical trial

Saatchi

Aghamohammadzadeh

Beheshtirouy

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

Okra (Abelmoschus esculentus) has traditionally been used in diabetes treatment. This study investigated the effect of Okra whole fruit on blood glucose level of patients with diabetes mellitus type 2 with concomitant use of oral hypoglycemic agents. In this double-blind randomized clinical trial, 120 diabetic patients were assigned to okra group (n = 60) and control group (n = 60). The okra group received 1,000 mg of A.esculentus whole fruit capsules orally, every 6 hr for 8 weeks. The control group received placebo capsule in the same manner. The levels of FBS (fasting blood sugar), BS (blood sugar), and Hemoglobin A1C (HgA1c) were measured at baseline and after intervention in both groups. The levels of FBS, BS, and HgA1c were significantly decreased in okra group within the intervention compared to control group (p < .05).Moreover, the numbers to treat (NNT) for FBS, BS, and HgA1C were seven, eight, and seven, respectively. Okra whole fruit supplementation has a promising antihyperglycemic effect in patients with diabetes mellitus type 2 who received oral agents. Diabetic patients could benefit from adjuvant therapy of okra with other medication.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti‐hyperglycemic effect of Abelmoschus culentesus (Okra) on patients with diabetes type 2: a randomized clinical trial

Saatchi

Aghamohammadzadeh

Beheshtirouy

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…A beneficial effect of IQP-AE-103 on the lipid metabolism was also demonstrated in the subgroup of subjects with baseline total cholesterol levels above 6.2 mmol/L. The study indicated that IQP-AE-103 could be an effective and safe weight loss intervention; the trial was registered with NCT03058367 [ 140 ]. However, currently, a trial to evaluate the glycemic evaluation of okra seed noodles is currently active, although not recruiting; see ( Identifier: NCT03990844).…”

Section: Safety and Efficacymentioning

confidence: 99%

Okra (Abelmoschus Esculentus) as a Potential Dietary Medicine with Nutraceutical Importance for Sustainable Health Applications

et al. 2021

View full text Add to dashboard Cite

Recently, there has been a paradigm shift from conventional therapies to relatively safer phytotherapies. This divergence is crucial for the management of various chronic diseases. Okra (Abelmoschus esculentus L.) is a popular vegetable crop with good nutritional significance, along with certain therapeutic values, which makes it a potential candidate in the use of a variety of nutraceuticals. Different parts of the okra fruit (mucilage, seed, and pods) contain certain important bioactive components, which confer its medicinal properties. The phytochemicals of okra have been studied for their potential therapeutic activities on various chronic diseases, such as type-2 diabetes, cardiovascular, and digestive diseases, as well as the antifatigue effect, liver detoxification, antibacterial, and chemo-preventive activities. Moreover, okra mucilage has been widely used in medicinal applications such as a plasma replacement or blood volume expanders. Overall, okra is considered to be an easily available, low-cost vegetable crop with various nutritional values and potential health benefits. Despite several reports about its therapeutic benefits and potential nutraceutical significance, there is a dearth of research on the pharmacokinetics and bioavailability of okra, which has hampered its widespread use in the nutraceutical industry. This review summarizes the available literature on the bioactive composition of okra and its potential nutraceutical significance. It will also provide a platform for further research on the pharmacokinetics and bioavailability of okra for its possible commercial production as a therapeutic agent against various chronic diseases.

show abstract

“…IQP-AE-103 is a combination of dehydrated powder of okra pods [ Abelmoschus esculentus (L.) Moench] and inulin, a heterogeneous mixture of fructose polymers extracted from chicory roots ( 14 , 15 ). This study demonstrated significant weight loss, a reduction in feelings of hunger, and a decrease in BMI, body fat mass, and waist and hip circumference as compared with the placebo ( 13 ). Much of the noted benefits were thought to be the result of the dietary fat binding by IQP-AE-103 and the physicochemical swelling and gel-forming properties of okra pods, which have been shown to induce satiety in vivo ( 13 ).…”

Section: Introductionmentioning

confidence: 71%

“…In a previously published, double-blind, placebo-controlled, 12-week trial, overweight and moderately obese subjects on a hypocaloric diet were treated with IQP-AE-103 ( 13 ). IQP-AE-103 is a combination of dehydrated powder of okra pods [ Abelmoschus esculentus (L.) Moench] and inulin, a heterogeneous mixture of fructose polymers extracted from chicory roots ( 14 , 15 ).…”

Section: Introductionmentioning

confidence: 99%

Microbiota Composition and Diversity in Weight Loss Population After the Intake of IQP-AE-103 in a Double-Blind, Randomized, Placebo-Controlled Study

Peng¹,

Cooper

Costa³

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

The effect of the novel IQP-AE-103 (proprietary combination of dehydrated okra powder and inulin) on body weight reduction and the association with changes in microbiota composition were investigated in a double-blind, randomized, placebo-controlled trial. A total of seventy-two overweight or moderately obese subjects with a body mass index of ≥25 and <35 kg/m2 were randomly allocated to receive IQP-AE-103 or placebo; each group received two IQP-AE-103 or placebo capsules three times daily, respectively. Body weight, body fat, waist circumference, and hip circumference were measured, and fecal samples were collected at baseline and after 12 weeks of intervention. Using 16S rRNA gene sequencing on the fecal samples, the microbiota dissimilarity, diversity, and differences in relative abundance between or within groups were analyzed. At the end of the study, body weight was significantly reduced in the IQP-AE-103 group compared with the placebo group, 5.16 ± 2.39 kg vs. 0.97 ± 2.09 kg (p < 0.001). Subjects from the IQP-AE-103 group who achieved a reduction of ≥5% of total body weight from baseline (hereafter referred to as 5% responders or IQP5) had a mean body weight reduction of 6.74 ± 1.94 kg, significantly greater than the placebo group (p < 0.001). Using Lefse and statistical analysis, subjects in the IQP-AE-103 group had a significantly lower relative abundance of Firmicutes than the placebo group (p < 0.05) after 12 weeks of intervention. The 5% responders from the IQP-AE-103 group had a remarkable 4.6-fold higher relative abundance of Akkermansia muciniphila than the placebo group (p < 0.05). As the significant differences between groups were only observed post-intervention, the overall differences in microbiota profile suggest that the weight loss in overweight and moderately obese subjects who consumed IQP-AE-103 for 12 weeks is accompanied by a positive change in microbiota composition. These changes might be linked to the beneficial effects of microbiome modulations in alleviating obesity and metabolic syndrome. To the best of our knowledge, we are the first to report over-the-counter (OTC) supplementation that results in both significant changes in weight and favorable shifts on the subject microbiota profile. The trial is registered under ClinicalTrials.gov Identifier no. NCT03058367.

show abstract

Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects

Cited by 10 publications

References 47 publications

Anti‐hyperglycemic effect of Abelmoschus culentesus (Okra) on patients with diabetes type 2: a randomized clinical trial

Anti‐hyperglycemic effect of Abelmoschus culentesus (Okra) on patients with diabetes type 2: a randomized clinical trial

Okra (Abelmoschus Esculentus) as a Potential Dietary Medicine with Nutraceutical Importance for Sustainable Health Applications

Microbiota Composition and Diversity in Weight Loss Population After the Intake of IQP-AE-103 in a Double-Blind, Randomized, Placebo-Controlled Study

Contact Info

Product

Resources

About